Exelixis Inc Restricted Cash and Investments, Current
Exelixis Inc (EXEL) had Restricted Cash and Investments, Current of $504.00 thousand as of 2018-09-28, per its 10-Q filed 2018-11-01.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Restricted Cash and Investments, Current
us-gaap:RestrictedCashAndInvestmentsCurrent · last filed 2018-11-01
- 2018-09-28: Restricted Cash and Investments, Current $504.00K.
- 2018-06-29: Restricted Cash and Investments, Current $504.00K.
- 2018-03-30: Restricted Cash and Investments, Current $504.00K.
- 2017-12-29: Restricted Cash and Investments, Current $504.00K.
| Period end | Restricted Cash and Investments, Current |
|---|---|
| 2018-09-28 | $504.00K 10-Q · filed 2018-11-01 |
| 2018-06-29 | $504.00K 10-Q · filed 2018-08-01 |
| 2018-03-30 | $504.00K 10-Q · filed 2018-05-02 |
| 2017-12-29 | $504.00K 10-Q · filed 2018-11-01 |
| 2017-09-29 | $0.00 10-Q · filed 2018-11-01 |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-01 |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-02 |
| 2016-12-30 | $0.00 10-Q · filed 2018-11-01 |
| 2015-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-10 |
| 2015-06-30 | $6.11M 10-Q · filed 2015-08-11 |
| 2015-03-31 | $6.11M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $12.21M 10-K · filed 2016-02-29 |
| 2014-09-30 | $12.21M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $12.21M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $12.21M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $12.21M 10-K · filed 2015-03-02 |
| 2013-09-30 | $12.21M 10-Q · filed 2013-10-30 |
| 2013-06-30 | $12.21M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $12.21M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $12.25M 10-K · filed 2014-02-20 |
| 2012-09-30 | $12.24M 10-Q · filed 2012-11-07 |
| 2011-12-31 | $0.00 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |